Let’s Talk Nutrition With Nico Episode 2: Why Menopause Research Needs a Life-Stage Approach to Clinical Validation

The second episode of Let’s Talk Nutrition with Nico, a collaborative video series between Lana Pine of The Educated Patient and Nicholas Saraceno of Nutritional Outlook, centers on women's health, with a particular focus on menopause and the importance of life-stage-specific clinical research. Saraceno highlights recent findings from a large longitudinal study of more than 10,000 postmenopausal Black and White women that linked premature natural menopause—defined as menopause occurring before age 40—to a 40% higher lifetime risk of coronary heart disease.

The findings, which remained consistent across racial groups, underscore the long-term health implications associated with menopausal timing and reinforce the need for greater scientific attention to this stage of life.

Building on that research, Saraceno examines how the nutraceutical industry is approaching menopause-related health concerns. He references commentary from Isabelle Raymond, PhD, senior vice president of clinical and medical affairs at Nutrafol, who argues that women experiencing perimenopause and menopause have unique physiological and behavioral characteristics that are often underrepresented in traditional dietary supplement studies.

According to Raymond, nutritional interventions intended for specific populations should be evaluated within those populations to accurately assess their biological effects and real-world relevance.

The conversation explores a broader shift occurring within clinical research, moving away from generalized study designs toward more targeted investigations that reflect distinct life stages and health experiences. Saraceno notes that representative research can provide more meaningful data on outcomes that matter to specific populations, whether related to metabolism, hair health, hormonal changes, or other concerns associated with menopause and aging.

The episode concludes with a discussion about consumer trust and scientific rigor. Both senior editors emphasize that stronger clinical validation can help improve confidence in menopause-focused products while supporting more accurate efficacy claims. Ultimately, the discussion frames life-stage-specific research not only as a scientific necessity but also as a critical step toward developing health solutions that better reflect the needs of the populations they are intended to serve.

A transcript of Pine’s and Saraceno’s conversation can be found below.

Lana Pine: I’m Lana Pine, senior editor of The Educated Patient, and welcome to our second episode of “Let’s Talk Nutrition with Nico,” a collaborative video series featuring The Educated Patient and Nutritional Outlook. I’m joined by Nico Saraceno, senior editor of NO. Thanks for being here, Nico!

Nicholas Saraceno: Of course, Lana. I’m so glad they decided to renew us for another episode!

Pine: This is true. So what’s on your mind today?

Saraceno: Well, since we’re all about themes on this show, I think it’s still very important to acknowledge that May was National Women’s Health Month. I know that Educated Patient has done quite a bit of coverage in the area, understanding brain fog to PCOS-friendly Hawaiian pineapple teriyaki burgers. We’re on the same wavelength with NO too—we’ve even got a one-day conference called “The Outlook on Women’s Wellness”—which we’ve all been very excited about. That’s why I thought that menopausal transition—the entire lifecycle of premenopause, perimenopause, and menopause—would be perfect to discuss.

Pine: Do tell!

Saraceno: First, let me just start by saying that I found an article you published back in March was very interesting. You discussed¹ how a large new study² tracking more than 10,000 postmenopausal Black and White women over several decades (between 1964 and 2018) found that premature natural menopause, defined as menopause occurring before age 40, is associated with a 40% higher lifetime risk of coronary heart disease (CHD) compared with women who reach menopause at a typical age. Just for context, more than 2 million women in the United States enter menopause annually. The findings held consistently across both Black and White women, making this one of the most comprehensive studies to examine this connection across racial groups.

The reason why I bring this up is that it draws attention to the need for life stage-specific clinical research, especially when it comes to the menopause nutraceuticals industry.

In an article examining gaps in clinical validation, Isabelle Raymond, PhD, senior vice president of clinical and medical affairs at Nutrafol, emphasized that women experiencing perimenopause and menopause have distinct physiological and behavioral needs that may not be adequately represented in traditional supplement trials.

She notes that, “Nutritional needs evolve and supplements designed to support specific outcomes must be studied not only in the population it is intended for, but also within the life stage they aim to address to capture their true biological impact.

The article argues that population-specific studies may improve the relevance and credibility of efficacy claims while supporting greater consumer confidence in menopause-focused products.

Pine: Woah, that’s interesting! Could you elaborate?

Saraceno: So, in a nutshell, the premise is that clinical research must move away from generalized "one-size-fits-all" models toward intentional, life-stage-specific studies that reflect real-world physiological experiences. Traditional research often fails to capture the nuances of specific populations, such as perimenopausal women, postpartum individuals, etc. By ensuring study participants are representative of the life stage being addressed, researchers can move beyond assumptions and extrapolation to provide results that are relevant and accurate.

Focusing on specific populations allows scientists to measure outcomes that truly matter to those groups. For example, studying supplements in perimenopausal women can identify specific impacts on metabolism and hair health, while research for postpartum women can better address safety and efficacy during hormonal shifts. This targeted approach provides consumers with necessary assurance that products are scientifically validated for their unique needs.

Ultimately, this shift toward life-stage-specific research is essential for fostering long-term consumer trust. Regulatory and scientific standards are increasingly emphasizing the importance of representative data, moving the industry toward a standard of rigor that matches how people actually live. Investing in this type of research is not just a matter of good science, Dr. Raymond notes, but a necessary step to building products and systems that effectively serve the people who use them.

Pine: So… what’s next?

Saraceno: I think that putting in the time to address this issue of investing in clinical testing needs to be made. Dr. Raymond put it best in saying that, “health doesn’t exist in a vacuum and neither should research. If meaningful innovation starts with meaningful science, then it’s time to ask why life stages experienced by so many remain overlooked in the studies meant to serve them.”

Pine: Truly powerful. Thanks for sharing, Nico.

Saraceno: Of course. Didn’t mean to get too heavy, but sometimes, it’s got to be done.

Pine: I agree, and thanks for taking the time today to share.

Saraceno: Definitely. Already looking forward to the next episode!

References

1. Pine L. Menopause before 40 raises lifetime heart disease risk by 40%. The Educated Patient. March 22, 2026. Accessed May 29, 2026. https://www.theeducatedpatient.com/view/menopause-before-40-raises-lifetime-heart-disease-risk-by-40-

2. Freaney PM, Ning H, Carnethon M, et al. Premature menopause and lifetime risk of coronary heart disease. JAMA Cardiol. 2026;11(5):455-458. doi:10.1001/jamacardio.2026.0212.